Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

by Cattan, S., Chan, S.L, Cheng, A.-L, Daniele, B., Edeline, J., Fartoux, L., Finn, R.S, Gurary, E.B, KEYNOTE-224 Investigators, Knox, J., Kudo, M., Ogasawara, S., Palmer, D.H, Sarker, D., Siegel, A.B, Verset, G., Verslype, C., Vogel, A., Wang, A., Yau, T., Zagonel, V., Zhu, A.X
Published 2022